ESMO Guidance for Reporting Oncology real-World evidence (GROW)

• L. Castelo-Branco,
• A. Pellat,
• D. Martins-Branco,
• A. Valachis,
• J.W.G. Derksen,
• K.P.M. Suijkerbuijk,
• U. Dafni,
• T. Dellaporta,
• A. Vogel,
• A. Prelaj,
• R.H.H. Groenwold,
• H. Martins,
• R. Stahel,
• J. Bliss,
• J. Kather,
• N. Ribelles,
• F. Perrone,
• P.S. Hall,
• R. Dienstmann,
• C.M. Booth,
• G. Pentheroudakis,
• S. Delaloge,
• M. Koopman

Affiliations

L. Castelo-Branco

Scientific and Medical Division, European Society for Medical Oncology (ESMO), Lugano, Switzerland; Correspondence to: Dr Luis Castelo-Branco, Scientific and Medical Division, European Society for Medical Oncology (ESMO), Via Ginevra 4, CH-6900 Lugano, Switzerland. Tel: +41-(0)91-973-19-00

A. Pellat

Department of Gastroenterology and Digestive Oncology, Hôpital Cochin AP-HP, Université Paris Cité, Paris; Centre d’Épidémiologie Clinique, Hôtel Dieu, Paris, France

D. Martins-Branco

Scientific and Medical Division, European Society for Medical Oncology (ESMO), Lugano, Switzerland; Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (HUB), Institut Jules Bordet, Academic Trials Promoting Team (ATPT), Brussels, Belgium

A. Valachis

Department of Oncology, Faculty of Medicine and Health, Örebro University Hospital, Örebro University, Örebro, Sweden

J.W.G. Derksen

Julius Center for Health Sciences and Primary Care, Department of Epidemiology and Health Economics, University Medical Centre Utrecht, Utrecht University, Utrecht

K.P.M. Suijkerbuijk

Department of Medical Oncology, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands

U. Dafni

Laboratory of Biostatistics, Department of Nursing, National and Kapodistrian University of Athens, Athens; Frontier Science Foundation Hellas, Athens, Greece

T. Dellaporta

Frontier Science Foundation Hellas, Athens, Greece

A. Vogel

Department of Gastroenterology, Hepatology and Endocrinology, Medical School of Hannover, Hannover, Germany; Toronto Center of Liver Disease, Toronto General Hospital, University Health Network, Toronto; Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada

A. Prelaj

AI-ON-Lab, Medical Oncology Department, Fondazione IRCCS Istituto Nazionale Tumori, Milan; NEARLab, Department of Electronics, Information and Bioengineering, Politecnico di Milano, Milan, Italy

R.H.H. Groenwold

Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands

H. Martins

Business Research Unit, ISCTE Business School, ISCTE-IUL, Lisbon, Portugal

R. Stahel

ETOP IBCSG Partners Foundation, Bern, Switzerland

J. Bliss

ICR-CTSU, Division of Clinical Studies, The Institute of Cancer Research, London, UK

J. Kather

Else Kroener Fresenius Center for Digital Health, Technical University Dresden, Dresden; Medical Oncology, National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany

N. Ribelles

Medical Oncology Intercenter Unit, Regional and Virgen de la Victoria University Hospitals, IBIMA, Málaga, Spain

F. Perrone

Clinical Trial Unit, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy

P.S. Hall

Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK

R. Dienstmann

Oncoclinicas Precision Medicine, Oncoclinicas Group, São Paulo, Brazil; Oncology Data Science Group, Vall d’Hebron Institute of Oncology, Barcelona, Spain

C.M. Booth

Department of Oncology; Department of Public Health Sciences, Queen’s University, Kingston, Canada

G. Pentheroudakis

Scientific and Medical Division, European Society for Medical Oncology (ESMO), Lugano, Switzerland

S. Delaloge

Department of Cancer Medicine, Gustave Roussy, Villejuif, France

M. Koopman

Department of Medical Oncology, University Medical Centre Utrecht, Utrecht University, Utrecht, The Netherlands